Hansa Biopharma AB Stock Nasdaq Stockholm
Equities
SE0002148817
Biotechnology & Medical Research
Sales 2024 * | 239M 21.98M | Sales 2025 * | 343M 31.48M | Capitalization | 1.5B 138M |
---|---|---|---|---|---|
Net income 2024 * | -735M -67.53M | Net income 2025 * | -712M -65.41M | EV / Sales 2024 * | 8.24 x |
Net Debt 2024 * | 474M 43.55M | Net Debt 2025 * | 733M 67.38M | EV / Sales 2025 * | 6.51 x |
P/E ratio 2024 * |
-2.36
x | P/E ratio 2025 * |
-2.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anders Pedersen
BRD | Director/Board Member | 73 | 18-05-28 |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
1st Jan change | Capi. | |
---|---|---|
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+45.26% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |